Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of SPY002-091 in Healthy Participants
NCT06672718Phase 1Completed
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SPY002 in inflammatory bowel disease (IBD) (4 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoint: Treatment Emergent Adverse Events at 40 weeks. Started Nov 2024; status: completed.
02
Drugs
SPY002
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06672718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672718.